United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $553.83, for a total transaction of $5,261,385.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,437,314.79. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Trading Down 2.2%

UTHR stock opened at $544.62 on Tuesday. The company has a market cap of $23.12 billion, a price-to-earnings ratio of 20.10, a PEG ratio of 1.81 and a beta of 0.60. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The firm has a 50-day moving average of $566.86 and a two-hundred day moving average of $516.87.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.63 EPS. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in UTHR. Wellington Management Group LLP boosted its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new position in United Therapeutics in the 3rd quarter valued at approximately $317,617,000. Norges Bank purchased a new position in United Therapeutics in the 4th quarter valued at approximately $293,418,000. Avoro Capital Advisors LLC boosted its position in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC boosted its position in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after buying an additional 341,383 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.